Peripheral Four-wavelength Near-infrared Spectroscopy Measurement: a Comparison Between EQUANOX and O3 in Cardiac Surgery (NIRS-8)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- Hôpital Cardiovasculaire et Pneumologique Louis Pradel, Hospices Civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >18 years
- Scheduled for conventional elective cardiac surgery with cardiopulmonary bypass
- Hospitalized in the Teaching University Hospital Louis Pradel (Lyon, France)
- Patient agreement
Exclusion Criteria:
- Age<18 years
- Black skin
- Emergencies
- Patient refusal
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peripheral absolute rSO2 values
Time Frame: at conventional cardiac surgery (Day 1)
|
Peripheral absolute rSO2 values given by the 4-wavelength EQUANOX device 7600 (Nonin Medical, Plymouth, Mn) and the new O3 device (Masimo, Irvine, CA) during conventional cardiac surgery.
|
at conventional cardiac surgery (Day 1)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arterial pressure
Time Frame: at conventional cardiac surgery (Day 1)
|
General monitoring
|
at conventional cardiac surgery (Day 1)
|
|
heart rate
Time Frame: at conventional cardiac surgery (Day 1)
|
General monitoring
|
at conventional cardiac surgery (Day 1)
|
|
pulse oxygen saturation
Time Frame: at conventional cardiac surgery (Day 1)
|
General monitoring
|
at conventional cardiac surgery (Day 1)
|
|
bispectral index
Time Frame: at conventional cardiac surgery (Day 1)
|
General monitoring
|
at conventional cardiac surgery (Day 1)
|
|
Inotrope drugs doses
Time Frame: at conventional cardiac surgery (Day 1)
|
at conventional cardiac surgery (Day 1)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jean-Luc Fellahi, Pr, MD PhD, Hôpital Cardiovasculaire et Pneumologique Louis Pradel, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 69HCL16_0502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.